Robert Orlowski, Director of Myeloma Section at MD Anderson Cancer Center, shared on X:
“Myeloma Paper of the Day: University Hospital of Salamanca’s experience with T-cell redirecting therapies in triple-class refractory myeloma suggests OS is better with CAR T approaches vs. bispecifics and CAR T failure best salvaged with bispecific antibodies.”
Authors: Borja Puertas, Adolfo Fernández-Sánchez, Elena Alejo, Beatriz Rey-Bua, Ana África Martín-López, Estefaía Pérez López, Miriam Lopez-Parra, Lucia Lopez-Corral, Norma Gutierrez, Ramón García-Sanz, Noemi Puig, Veronica Gonzalez-Calle, and Maria-Victoria Mateos.
Source: Robert Orlowski/X
Other insights by Robert Orlowski on OncoDaily.
